Phone: (707) 546-5553
Email Us
1140 Sonoma Avenue 1-A
Santa Rosa, CA 95405

HIFU is now FDA approved

Key ingredients to thwart the growth of prostate cancer found in certain foods

When you dine on curry and baked apples, enjoy the fact that you are eating something that could play a role starving — or even preventing — cancer.

New research from The University of Texas at Austin identifies several natural compounds found in food, including turmeric, apple peels and red grapes, as key ingredients that could thwart the growth of prostate cancer, the most common cancer afflicting U.S. men.

Published online this week in Precision Oncology, the new paper uses a novel analytical approach to screen numerous plant-based chemicals instead of testing a single agent as many studies do, discovering specific combinations that shrink prostate cancer tumors.

“After screening a natural compound library, we developed an unbiased look at combinations of nutrients that have a better effect on prostate cancer than existing drugs,” says corresponding author Stefano Tiziani, assistant professor in the Department of Nutritional Sciences and Dell Pediatric Research Institute at UT Austin. “The beauty of this study is that we were able to inhibit tumor growth in mice without toxicity.”

During the past decade, some cancer research has highlighted the potential therapies found in plants, including chemicals found in foods such as turmeric, apple peels and green tea. These compounds minimize one of the risk factors for cancer, inflammation within the body. People who have chronic inflammation because of chronic infection, autoimmune disease or conditions such as obesity have a higher cancer risk because of damage to normal cells.

The researchers first tested 142 natural compounds on mouse and human cell lines to see which inhibited prostate cancer cell growth when administered alone or in combination with another nutrient. The most promising active ingredients were then tested on model animals: ursolic acid, a waxy natural chemical found in apple peels and rosemary; curcumin, the bright yellow plant compound in turmeric; and resveratrol, a natural compound common to red grapes or berries.

“These nutrients have potential anti-cancer properties and are readily available,” says Tiziani. “We only need to increase concentration beyond levels found in a healthy diet for an effect on prostate cancer cells.”

The new research paper also demonstrates how the plant-based chemicals work together. Combining ursolic acid with either curcumin or resveratrol prevents cancer cells from gobbling something that they need to grow, glutamine. This is a neat solution: blocking the uptake of a nutrient needed by prostate cancer cells with nutrients that are commonly in the human diet.


Story Source:

Materials provided by University of Texas at Austin. Note: Content may be edited for style and length.


Journal Reference:

  1. Alessia Lodi, Achinto Saha, Xiyuan Lu, Bo Wang, Enrique Sentandreu, Meghan Collins, Mikhail G. Kolonin, John DiGiovanni, Stefano Tiziani. Combinatorial treatment with natural compounds in prostate cancer inhibits prostate tumor growth and leads to key modulations of cancer cell metabolism. npj Precision Oncology, 2017; 1 (1) DOI: 10.1038/s41698-017-0024-z

Read this article on Science Daily: University of Texas at Austin. “Starving prostate cancer with what you eat: Apple peels, red grapes, turmeric.” ScienceDaily. ScienceDaily, 6 June 2017. www.sciencedaily.com/releases/2017/06/170606112750.htm.

Sonablate HIFU Tissue Change Monitoring

HIFU, which stands for high intensity focused ultrasound is a recently approved new technology for prostate tissue ablation. Many urologists have worked with HIFU for several years to offer their patients a minimally invasive treatment option for prostate cancer, either as a part of a clinical trial or at international treatment centers outside the United States.

There are currently two different medical devices that use HIFU energy to heat and destroy tissue in the prostate. The most technologically advanced HIFU device for prostate cancer is called the Sonablate. The Sonablate is a software directed device that includes a computer console, a transrectal probe and a chilling unit. The Sonablate software that physicians use to plan and execute Sonablate HIFU treatment has state-of-the-art features that make it the safest and most precise HIFU device for prostate disease available.

Using the Sonablate state-of-the-art software physicians obtain real-time images of the prostate that are used to map out and target exactly where HIFU should be delivered. Once treatment plan is mapped, HIFU energy is delivered to those areas.

One of the unique key features that the Sonablate has is called Tissue Change Monitoring, or more simply, TCM.

What is TCM?

The most simple way to explain it is that TCM allows the treating HIFU doctor to monitor changes that happen to the tissue in the prostate after the HIFU energy has been delivered. This monitoring of tissue is important because the doctor will immediately know if enough energy has been delivered to effectively destroy the tissue.

While HIFU is being delivered to heat and destroy tissue in the prostate, physicians have the ability to monitor how the tissue is changing and reacting. The Sonablate gives unique feedback on changes to the tissue so the doctor can monitor exactly what is happening and make adjustments as needed for the best outcomes.

Read the full story here …

High-intensity focused ultrasound or HIFU has many proven advantages over traditional treatment modalities for prostate disease. Visit our website to learn More: www.californiahifu.com #prostatecancer #HIFU #prostate #menshealth

By | December 20th, 2016|HIFU, News, Prostate Cancer|0 Comments

Santa Rosa Urologist Dr. Michael Lazar is Making History with a Nonsurgical, Outpatient Treatment for Prostate Cancer

Dr. Lazar and his staff are proud to be early leaders in the usage of HIFU.

Dr. Lazar and his staff are proud to be early leaders in the usage of HIFU.

High-intensity focused ultrasound (HIFU) waves target cancer cells with precision in a one-to-four-hour procedure that has little or no side affects and a quick recovery rate, giving those diagnosed with prostate cancer another choice over surgery or radiation.

HIFU has been used in other countries for years, and Dr. Lazar has been instrumental in bringing this innovative treatment to the United States. It was approved by the Food and Drug Administration last October, and he has since been performing the procedure at San Francisco Surgery Center for patients who travel from across the country to receive this leading edge treatment.

“The oncological results for HIFU are broadly comparable to radical surgery or radiation but the side effects are less,” says Dr. Lazar. “If the HIFU procedure is performed in the morning, a patient is typically up and around by dinnertime and can often return to normal activity within a few days without the use of pain-killers.”

Dr. Lazar has recently become involved with HIFU Prostate Services, LLC as their Medical Director.  HIFU Prostate Services is the first company to establish centers in the United States offering Sonablate HIFU technology. HIFU Prostate Services makes the non-invasive treatment option available through partnerships with some of the largest urology practices and experienced physicians that establish Sonablate HIFU Centers of Excellence.  Urologists are able to create their own HIFU program and offer treatment within their region. These centers also offer training and proctorship opportunities.

Along with serving as the Medical Director of HIFU Prostate Services, LLC. Dr. Lazar is also a clinical partner with his HIFU Center of Excellence at the state-of-the-art SFSC in downtown San Francisco. Dr. Lazar and his staff are proud to be early leaders in the usage of HIFU. He has worked tirelessly with SonaCare, the manufacturer of the instruments, to bring this innovative service for prostate cancer treatment to patients in the United States.

The HIFU technique is also being developed to treat many other types of cancer including breast, uterine, liver, kidney, and brain.

For those with prostate cancer, HIFU treatment is most effective for patients with early stage cancer, where it is localized to the prostate. It is performed on an out-patient basis that takes one to four hours. A urinary catheter is placed after the procedure for one to three weeks.

While some patients might experience slight irritation, “some patients can have a catheter and they don’t even know it.”

The procedure preserves healthy tissue and nerves, so urine flow and erectile function is maintained in a high percent of cases, as compared to radical surgery or radiation.

Another advantage is recovery time. With surgery or radiation treatment, recuperation time for patients is six to eight weeks, whereas HIFU patients return to normal activities within days.

Dr-michael-lazarDr. Lazar has been treating U.S. prostate cancer patients in Mexico since 2007, where he performed hundreds of outpatient procedures at a U.S. Joint Commission approved bilingual hospital. There, he also served as a HIFU instructor for other physicians and is now training doctors in San Francisco.

Because the treatment is so new, it will take another couple of years before it will be routinely covered by insurance. Those with non-Medicare insurance may get reimbursed to varying degrees.

“What will really make this explode is when the insurance companies are routinely covering the procedure and it will become widely available to all patients. The costs for this procedure are drastically less than for radical surgical and radiation procedures, and with fewer complications so insurance companies will be incentivized to cover it,” Dr. Lazar commented.

As soon as more doctors are trained to perform the procedure in San Francisco, Dr. Lazar plans to bring the treatment to his Santa Rosa office.

“I expect as word gets out there will be a progressive demand for this procedure, so training physicians will be a high priority. It’s already expanding rapidly and we put in an order for our tenth machine,” said Dr. Lazar, adding he won’t be giving up his general urology practice any time soon. “This is what I love to do.”

 

 

 

HIFU Center of Excellence in San Francisco

HIFU 4.12 pic 1Sonablate HIFU is available now with Dr. Michael Lazar at HIFU Center of Excellence In San Francisco located in downtown San Francisco, 450 Sutter Street, Suite 500, San Francisco, CA 94108

HIFU Center of Excellence offers patients a state-of-the-art facility in downtown that is convenient to hotels and the airport for patients interested in traveling from around the country for this recently FDA-cleared treatment. For more information about HIFU treatment which is now available in San Francisco, or to make an appointment call: (707) 546-5553. Visit us online to learn more at: www.californiahifu.com

HIFU 4.12 pic 1.2Physician Practicing HIFU in San Francisco: Dr. Michael Lazar

See more on the HIFU Prostate Services Website.

By | April 12th, 2016|Dr. Michael Lazar, HIFU, News|0 Comments

Prostate cancer treatment which avoids harming sexual performance soon available on NHS

A revolutionary prostate cancer treatment which avoids harming men’s sexual performance could soon be available on the NHS.

High Intensity Focused Ultrasound kills the tumour with heat without damaging healthy tissue around it.

In an NHS trial led by University College Hospital, London, 625 men were treated. After five years 93% were cancer-free.

Only 15% had erectile problems compared with 30 to 60% following surgery.

The results were revealed to the European Association of Urology in Munich.

 

Read the full story …

By | April 5th, 2016|HIFU, News, Prostate Cancer, Testimonials|0 Comments

HIFU Prostate Services Expands Management Team with Chief Operating Officer

John McLean brings significant amount of experience in HIFU, operations, marketing and medical imaging.

CHARLOTTE, N.C. March 9, 2016. HIFU Prostate Services, LLC, a leading provider of minimally invasive prostate cancer treatments using high intensity focused ultrasound (“HIFU”), is pleased to announce the addition of John McLean as chief operating officer. McLean brings 17 years of experience in healthcare marketing and management to HIFU Prostate Services and will be responsible for managing treatment teams, training programs and marketing initiatives.

Prior to joining HIFU Prostate Services, McLean spent eight years at SonaCare Medical where he was involved in approximately 600 HIFU cases. While at SonaCare Medical, McLean served as product manager, business manager and service engineer; he brings experience in all areas of running a successful HIFU business.

“After working with John McLean at SonaCare Medical for eight years, it was clear that HIFU Prostate Services could benefit significantly from his experience as we continue to partner with leading urologists and place HIFU systems in the U.S. market.  He will be instrumental in our continued growth and expansion,” said John W. Linn, chief executive officer of HIFU Prostate Services.

“After leaving SonaCare Medical in January, I knew I wanted to continue to work with HIFU technology and help make it more accessible for patients looking for a minimally invasive treatment option. I interviewed several different HIFU companies that are offering treatment as I searched for the one that excelled most in quality of patient care, physician development and advancement of the HIFU technology. It was clear that HIFU Prostate Services has the superior national platform with an experienced HIFU staff and physician network focused on excellent patient care and physician training,” said McLean.

Previously, McLean spent more than nine years in various leadership roles in healthcare ranging from medical imaging companies, healthcare service companies and the U.S. Army; these experiences give him a unique insight into the healthcare industry. McLean has set up and run healthcare support in hospitals, outpatient surgery centers and combat-support hospitals.

HIFU Prostate Services was the first company to offer treatment using Sonablate HIFU technology in November 2015. The company rapidly expanded operations into four centers that will treat nearly 30 patients in March and three additional centers are planned to open this spring.

“We are thrilled to have John on board; his role will focus on the continued growth of the company’s existing treatment centers and support expansion as the company adds six additional treatment locations in the coming months,” said John Harris, chairman of HIFU Prostate Services.

About HIFU Prostate Services, LLC

HIFU Prostate Services (HPS) is the nation’s leading provider of minimally invasive prostate cancer treatment using high intensity focused ultrasound. HPS was founded to provide men access to a less invasive treatment option for prostate cancer that has the ability to eliminate cancer and preserve patient quality of life. Our mission is to deliver the highest quality of care, support, and technology to the patient and to the urology community for the treatment of localized prostate cancer using high intensity focused ultrasound (HIFU) with the Sonablate. HPS was founded in 2015 by a seasoned management team with over 50 years of experience in the healthcare industry and over 30 years focused on HIFU technologies.

HPS has the most experienced HIFU staff in the country with over 60 years of combined HIFU experience. HPS nurses and technicians have been involved in over 3,000 HIFU procedures. The HPS network includes 100 physicians across the U.S., and our physician proctors have experience with over 1,200 HIFU procedures. The company is headquartered in Charlotte, NC and has established partnerships with physicians and urology practices throughout the country.

For more information about HIFU or to make an appointment call (707) 546-5553. Find us online at: www.californiahifu.com.

 

By | March 29th, 2016|Dr. Michael Lazar, HIFU, News|0 Comments

HIFU Prostate Services Names Michael J. Lazar, MD Medical Director

Nov. 4, 2015 — HIFU Prostate Services (HPS) has named Dr. Michael Lazar as HPS Medical Director. As HPS Medical Director Dr. Lazar will provide medical guidance and proctoring to new physicians that are being trained on the Sonablate® HIFU system in surgery centers around the country. HIFU offers an effective treatment for localized prostate cancer with significantly less risk of common side effects, such as impotence and incontinence, which are typically reported with surgery and radiation. Lazar has been treating with HIFU since 2007 and is one of three US physicians who worked with SonaCare Medical, LLC to supervise HIFU treatments during FDA clinical trials.

Dr. Lazar will operate his own HIFU Program, in partnership with HPS, offering prostate treatments in downtown San Francisco, near Union Square, at San Francisco Surgery Center (SFSC). SFSC offers patients a state-of-the-art facility in downtown that is convenient to hotels and the airport for patients interested in traveling from around the country for this recently FDA-cleared treatment.

By | November 11th, 2015|Dr. Michael Lazar, HIFU, News|0 Comments

HIFU Now Available In the U.S. Ending a Long Awaited FDA Approval Process

sonablate500After much anticipation the FDA has finally approved for market in the United States the Sonablate® for the ablation of prostate tissue. Sonablate® is the first High Intensity Therapeutic Ultrasound (HITU) device to receive FDA regulatory authorization for prostate tissue ablation. HIFU offers an effective treatment for localized prostate cancer with significantly less risk of common side effects, such as impotence and incontinence which are typically reported with surgery and radiation.

HIFU Prostate Services, LLC (HPS) is a leading provider of minimally-invasive prostate cancer treatments using High Intensity Focused Ultrasound (HIFU). Newly appointed HPS Medical Director Michael J. Lazar, MD is set to provide medical guidance and proctoring to new physicians who will now be trained on the Sonacare® HIFU system in surgery centers around the country. Dr. Lazar has been treating patients with HIFU since 2007 and is one of only three U.S. physicians who worked with SonaCare Medical, LLC to supervise HIFU treatments during FDA clinical trials.

John W. Linn, chief executive officer of HPS commented, “I have known Dr. Lazar since 2007 and have been impressed with his patient care and dedication to the HIFU technology since his first treatment. He is the ideal medical director for HPS and for teaching this new technology to US physicians.”

Dr. Lazar will also operate his own HIFU Program in partnership with HPS, offering prostate treatments in downtown San Francisco near Union Square at San Francisco Surgery Center (SFSC). SFSC offers patients a state-of-the-art facility that is convenient to hotels and the airport for patients interested in traveling from around the country for HIFU treatments. The actual Sonablate device has just been delivered to the Surgery Center in San Francisco, marking the first time ever that a HIFU device will be available at a medical center in the United States.

“It is very exciting to be a part of providing the vehicle for access to this technology for new and experienced HIFU users. Over the years, physicians in various stages of training have shown remarkable enthusiasm for providing HIFU for their prostate cancer patients, but they did not see a clear path for obtaining accessibility to the technology after FDA approval,” said Lazar. “HIFU Prostate Services takes the mystery and tedium out of the process by providing the highest quality of care, support and technology to the patient and to the urology community. Men who choose HIFU can contact HPS and then be referred to a regional HIFU surgeon. This approach facilitates wide availability of this treatment option for American men.”

HIFU offers patients a single, outpatient treatment for prostate cancer that is bloodless and allows men to return to their normal lifestyles within a few days. Although HIFU is designed as a single treatment, it can be repeated if needed. HIFU may also be used to treat patients that have failed radiation therapy and it does not preclude any future treatments including surgery or radiation.

About HIFU Prostate Services, LLC & Dr. Michael Lazar

At HIFU Prostate Services (HPS), our mission is to partner with physicians to deliver the highest quality of care, support and technology to the patient and to the urology community for the treatment of localized prostate cancer using high intensity focused ultrasound (HIFU). HPS was founded in 2015 by a seasoned management team with over 50 years of experience in the healthcare industry and over 30 years focused on HIFU technologies The company is headquartered in Charlotte, N.C.

lazar close upLazar has been certified by the American Board of Urology four times and has practiced in Santa Rosa, California since 1983. He is chairman of the Board of Redwood Health Services, Inc. providing insurance products for employee groups. Lazar is also CEO and managing director of Santa Rosa Surgical Management Company, LLC that manages the ambulatory surgery center at Santa Rosa Memorial Hospital. Lazar received his urology training at Louisiana State University in New Orleans, La. and is a graduate of University of Arkansas Medical School.

For additional information, visit Dr. Michael Lazar at www.californiahifu.com, 707-546-5553 or www.hifuprostateservices.com. Media Contact: John Linn, 704-737-5925

By | November 10th, 2015|Dr. Michael Lazar, HIFU, Prostate Cancer|0 Comments